フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
IMI announces three new skin sterol patents TORONTO, June 21 /PRNewswire-FirstCall/ -- Leading predictive medicine company IMI International...
Skin sterol correlates with presence of coronary calcium Simple, non-invasive test an effective tool to identify early heart disease TORONTO, June...
IMI plans change in name to PreMD Inc. New name reflects evolution of company from development-stage biotech to innovator in predictive medicine...
New skin sterol data to be presented at American Association for Clinical Chemistry meeting TORONTO, May 24 /PRNewswire-FirstCall/ -- Predictive...
IMI announces first quarter financial results and provides operational update - Lead cardiovascular test, PREVU(x) POC, made available for sale...
PREVU(x) study to open new markets PREVU(x) LT Skin Sterol Test included in 25,000-participant insurance industry study TORONTO, May 10...
IMI announces pivotal breast cancer test study Non-invasive, painless test designed to screen for early-stage disease TORONTO, May 4...
Skin sterol provides new information about heart disease risk PREVU(x) POC Skin Sterol Test has value in further stratifying intermediate-risk...
IMI announces fiscal 2004 financial results TORONTO, March 31 /PRNewswire-FirstCall/ -- IMI International Medical Innovations Inc. (TSX: IMI;...
IMI Announces First Acceptance of Patent for Color Measurement Process Technology used in PREVU(x) Skin Sterol Test as well as cancer products...
IMI provides operational update and previews fiscal 2004 results - Significantly advanced commercialization of PREVU(x) Skin Sterol Test...
IMI announces fiscal 2004 update conference call & webcast TORONTO, March 7 /PRNewswire-FirstCall/ -- IMI International Medical Innovations Inc...
Growing evidence that skin sterol is linked to hidden heart disease Simple, non-invasive test reveals coronary artery disease in patients with...
IMI files patent application for new format of skin sterol technology TORONTO, March 1 /PRNewswire-FirstCall/ -- IMI International...
IMI provides update on ARISE clinical trial TORONTO, Feb. 28 /PRNewswire-FirstCall/ -- Amendments approved last week by the U.S. Food and Drug...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約